Alector’s AbbVie-partnered Alzheimer's disease asset has failed to slow disease progression in a phase 2 study, the latest in ...
Alector is kicking off a resource realignment effort that will include a workforce reduction of around 17%. The biotech ...
Vigil Neuroscience's stock dropped after Alector's AL002 failed in Alzheimer's, raising concerns about VG-3927's efficacy.
Alector Therapeutics, working with AbbVie, was testing whether modulating immune cells in brain would slow Alzheimer's ...
To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Brain drug developer Alector is ...
Alector has significant cash reserves but faces high cash burn, with no immediate catalysts and uncertain prospects for its ...
GlobalData on MSN7d
Alector stock drops after Alzheimer’s drug fails in Phase II trial"Alector stock drops after Alzheimer’s drug fails in Phase II trial" was originally created and published by Clinical Trials ...
Alector, Inc. (NASDAQ:ALEC – Free Report) – HC Wainwright issued their Q1 2025 EPS estimates for shares of Alector in a ...
根据Alector发布的最新财务报告，公司的营业收入为1534万美元，而净利润则显示出公司面临严重亏损，达到了4222万美元，每股收益为-0.43美元。这样的业绩在生物技术行业中并不罕见，尤其是处于研发阶段的公司，但仍然可能令投资者对于未来的盈利能力产生质疑。此外，该公司目前的毛利为1315万美元，市盈率为-1.44倍，这一数据表明，市场对其未来盈利的预期相对负面。
根据最近向美国证券交易委员会提交的文件显示，Alector, Inc. (NASDAQ:ALEC)的首席医疗官Gary Romano出售了14,892股普通股。此次交易发生之际，该公司股票价格接近52周低点2.37美元，过去六个月内已下跌超过50%。根据 InvestingPro 分析，基于公允价值指标，该股票目前似乎被低估。这些股票于2024年12月2日以平均价格2.5194美元售出，总交易价值 ...
Alector, Inc.（纳斯达克股票代码：ALEC）的总裁兼研发主管Sara Kenkare-Mitra于12月2日出售了26,500股公司普通股。这家临床阶段生物制药公司目前市值2.46亿美元，其股票年初至今下跌近69%， InvestingPro ...
北京时间2024年12月03日02时39分，Alector, Inc.（ALEC.us）股票出现波动，股价急速跳水5.02%。截至发稿，该股报2.46美元/股，成交量144.382万股， 换手率 1.47%，振幅6.53%。
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback